Licensing Opportunities

Sanquin offers a broad range of licensing opportunities and monoclonal antibodies.

Current licensing opportunities

Personalized medicine within reach with Sanquin druglevel and immunogenicity tests (pdf)	Patent application P80957PC00
Enhanced RA treatment with a novel genotyping predictor test for IgG receptors (pdf)	Patent nr. WO2007073179/EP1801234
Increasing the therapeutic efficacy of IgG (pdf)	Patent application PCT/EP2008/000373
Aterial trombosis, next generation therapeutics (pdf)	RAG-35 & RAG-201 Monoclonal antibodies with potential anti-von Willebrand factor capacities. Indications: arterial thrombosis, thrombotic thrombocytopenic purpura, von Willebrands disease, etc.
Improved Safety & Stability Profile of Therapeutic Antibodies & IVIG (pdf)	Patent application P86777EP00
Breaking the boundaries for antibody therapy against cancer (pdf)	Patent application EP2111869A1
Improved detection of copy number variation and SNP's (pdf)	Patent nr. WO2010053363